• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    BioPlus Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    10/4/23 7:32:21 AM ET
    $BIOS
    Blank Checks
    Finance
    Get the next $BIOS alert in real time by email
    0001856653 false 0001856653 2023-10-04 2023-10-04 0001856653 BIOS:UnitsEachConsistingOfOneClassOrdinaryShareAndOnehalfOfOneRedeemableWarrantMember 2023-10-04 2023-10-04 0001856653 BIOS:ClassOrdinaryShareParValue0.0001PerShareMember 2023-10-04 2023-10-04 0001856653 BIOS:WarrantsEachExercisableForOneClassOrdinaryShareFor11.50PerShareMember 2023-10-04 2023-10-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(D)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): October 4, 2023

     

    BIOPLUS ACQUISITION CORP.

    (Exact name of registrant as specified in its charter)

     

    Cayman Islands   001-41116   98-1583872
    (State or other jurisdiction   (Commission File Number)   (I.R.S. Employer
    of incorporation)       Identification No.)

     

    260 Madison Avenue

    Suite 800

    New York, New York

      10026
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code (212) 287-4092

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Units, each consisting of one Class A Ordinary Share and one-half of one Redeemable Warrant   BIOSU   The Nasdaq Stock Market LLC
    Class A Ordinary Share, par value $0.0001 per share   BIOS   The Nasdaq Stock Market LLC
    Warrants, each exercisable for one Class A Ordinary Share for $11.50 per share   BIOSW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    As previously disclosed, on May 2, 2023, BioPlus Acquisition Corp., a Cayman Islands exempted company (“BIOS” or the “Company”), Guardian Merger Subsidiary Corp., a Delaware corporation and a direct wholly owned subsidiary of BIOS (“Merger Sub”), and Avertix Medical, Inc. (f/k/a Angel Medical Systems, Inc.), a Delaware corporation (“Avertix”), and, solely with respect to Section 3.03(b) and Section 7.21 of the Business Combination Agreement (as defined below), BioPlus Sponsor LLC, a Cayman Islands limited liability company (the “Sponsor”), entered into a business combination agreement and plan of reorganization (the “Business Combination Agreement”), pursuant to which Merger Sub will merge with and into Avertix (the “Merger”), with Avertix surviving the Merger as a direct wholly owned subsidiary of BIOS.

     

    On October 4, 2023, pursuant to Section 9.01(a) of the Business Combination Agreement, the parties to the Business Combination Agreement entered into a Termination and Release Agreement (the “Termination Agreement”) to terminate the Business Combination Agreement (the “Termination”). The Termination Agreement also automatically terminates ancillary documents to the Business Combination Agreement (the “Ancillary Documents”), including certain stockholder support agreements, by and among BIOS, Avertix and certain stockholders of Avertix (the “Stockholder Support Agreements”), and the sponsor support agreement, by and among BIOS, the Sponsor and Avertix (the “Sponsor Support Agreement”). Additionally, the Termination Agreement provides for a mutual release of claims among the parties and their affiliates.

     

    As a result of the Termination, the Business Combination Agreement is of no further force and effect, with the exception of specified provisions set forth in the Termination Agreement, and all provisions of the Ancillary Documents, including provisions of any such Ancillary Document that by their terms would otherwise have survived the termination of such Ancillary Document, is of no further force and effect.

     

    The foregoing descriptions of the Business Combination Agreement, the Termination Agreement and the Ancillary Documents do not purport to be complete and are qualified in their entirety by the terms and conditions of, respectively, (i) the Business Combination Agreement, a copy of which was previously filed as Exhibit 2.1 to BIOS’ Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on May 3, 2023, (ii) the Termination Agreement, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1, and the terms of which are incorporated by reference herein and (iii) the Stockholder Support Agreements and the Sponsor Support Agreement, copies of which were previously included as Exhibits 10.3 and 10.4 to BIOS’ Current Report on Form 8-K filed with the SEC on May 3, 2023.

     

    Item 1.02. Termination of Material Definitive Agreement.

     

    The information set forth in Item 1.01 above is hereby incorporated by reference into this Item 1.02.

     

    Item 8.01 Other Events.

     

    In view of the termination of the Business Combination Agreement, BIOS determined that it would be unable to consummate an initial business combination within the time period in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association, as amended (the “Charter”) and BIOS intends to dissolve and liquidate in accordance with the provisions of its Charter.

     

    BIOS expects to redeem all of its Class A ordinary shares that were included in the units issued in the Company’s initial public offering (“Public Shares”) for an estimated redemption price of approximately $10.79 per share (the “Redemption Amount”) after the payment of taxes and dissolution expenses. Record holders will receive their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company’s transfer agent. Beneficial owners of Public Shares held in “street name,” however, will not need to take any action in order to receive the Redemption Amount. The redemption of the Public Shares is expected to be completed within ten business days after October 4, 2023.

     

    1

     

     

    The Sponsor has agreed to waive its redemption rights with respect to its outstanding Class B ordinary shares issued prior to the Company’s initial public offering and the Class A ordinary shares contained in the units issued in a private placement concurrent with the initial public offering.

     

    There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless.

     

    On October 4, 2023, BIOS issued a press release announcing the termination of the Business Combination Agreement and its intent to liquidate. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    The following exhibits are filed herewith:

     

    Exhibit No.   Description of Exhibits
    10.1   Termination and Release Agreement, dated October 4, 2023, by and among BioPlus Acquisition Corp., Guardian Merger Subsidiary Corp., Avertix Medical, Inc., and BioPlus Sponsor LLC.
    99.1   Press Release dated October 4, 2023.
    104.1   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: October 4, 2023

     

      BioPlus Acquisition Corp.
           
      By: /s/ Ross Haghighat
        Name:  Ross Haghighat
        Title: Chief Executive Officer and Chief Financial Officer

     

     

    3

     

     

    Get the next $BIOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate

      New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. ("BIOS" or the "Company") (NASDAQ:BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization (the "Business Combination Agreement"), effective as of October 4, 2023 and (ii) it intends to liquidate as soon as practicable after October 4, 2023 and to return funds to holders of its Class A ordinary shares that were included in the units issued in the Company's initial public offering ("Public Shares"). The Business Combination Agreement was dated as of May 2, 2023. The pa

      10/4/23 7:30:00 AM ET
      $BIOS
      Blank Checks
      Finance
    • Avertix and BIOS Acquisition Corporation Mutually Agree to Terminate Proposed Business Combination

      EATONTOWN, N.J. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and BIOS Acquisition Corporation (dba BioPlus Acquisition Corp.) ("BIOS") (NASDAQ:BIOS), a special purpose acquisition company, announced today that the two companies have mutually agreed to terminate their proposed business combination. "While we were enthusiastic about the potential business combination with BIOS, we mutually agreed that the current market conditions are not co

      10/4/23 7:30:00 AM ET
      $BIOS
      Blank Checks
      Finance
    • Carbonhand is available for Veterans in the US

      Bioservo signs a Sales Agent agreement with Trivet Medical LLC for sales of Carbonhand to Hospitals, Clinics, and Medical Centers within the Veterans Health Administration and Department of Defense in the US. With the first Sales Agent in place, the grip-strengthening device Carbonhand is available for all US Veterans suffering from impaired hand function. KISTA, Sweden, Aug. 29, 2023 /PRNewswire/ -- Trivet Medical LLC is a specialized strategic sales and distribution LLC, highly focused on commercializing disruptive, best-in-class med-tech devices and technologies. Founded by Charles Coyle, Trivet Medical's mission is to develop underrepresented and underserved healthcare conditions through

      8/29/23 3:03:00 AM ET
      $BIOS
      Blank Checks
      Finance

    $BIOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Bioplus Sponsor Llc

      4 - BioPlus Acquisition Corp. (0001856653) (Issuer)

      6/12/23 9:17:36 PM ET
      $BIOS
      Blank Checks
      Finance

    $BIOS
    SEC Filings

    See more
    • SEC Form 15-12G filed by BioPlus Acquisition Corp.

      15-12G - BioPlus Acquisition Corp. (0001856653) (Filer)

      10/16/23 4:15:07 PM ET
      $BIOS
      Blank Checks
      Finance
    • SEC Form 25-NSE filed by BioPlus Acquisition Corp.

      25-NSE - BioPlus Acquisition Corp. (0001856653) (Subject)

      10/6/23 4:03:10 PM ET
      $BIOS
      Blank Checks
      Finance
    • SEC Form RW filed by BioPlus Acquisition Corp.

      RW - BioPlus Acquisition Corp. (0001856653) (Filer)

      10/4/23 7:39:57 AM ET
      $BIOS
      Blank Checks
      Finance

    $BIOS
    Financials

    Live finance-specific insights

    See more
    • Purple Innovation Announces Cooperative Framework with Coliseum Capital

      Company to Welcome New Directors to Board Adam Gray to Serve as Board Chair Gary DiCamillo to Continue to Serve as Lead Independent Director Company Will Redeem Cumulative Voting Proportional Representation Preferred Linked Stock Purple Innovation, Inc. (NASDAQ:PRPL) ("Purple" or the "Company"), a comfort innovation company known for creating the "World's First No Pressure® Mattress," today announced that it has entered into a binding Memorandum of Understanding to establish a cooperative governance framework (the "Planned Cooperation Agreement") with Coliseum Capital Management, LLC (together with its managed funds and accounts, "Coliseum"), the largest stockholder of the Company o

      4/13/23 4:05:00 PM ET
      $ADES
      $BIOS
      $LAZY
      $LOGI
      Major Chemicals
      Industrials
      Blank Checks
      Finance

    $BIOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

      SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

      2/12/24 4:14:06 PM ET
      $BIOS
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

      SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

      2/9/24 10:26:34 AM ET
      $BIOS
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

      SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

      2/7/24 2:00:23 PM ET
      $BIOS
      Blank Checks
      Finance